Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex.

MacKeigan, Jeffrey P; Krueger, Darcy A

MacKeigan, Jeffrey P; Krueger, Darcy A.

Affiliation

MacKeigan JP; Laboratory of Systems Biology, Van Andel Research Institute, Grand Rapids, Michigan (J.P.M.); Department of Pediatrics, Tuberous Sclerosis Clinic, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio (D.A.K.).
Krueger DA; Laboratory of Systems Biology, Van Andel Research Institute, Grand Rapids, Michigan (J.P.M.); Department of Pediatrics, Tuberous Sclerosis Clinic, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio (D.A.K.).

Neuro Oncol ; 17(12): 1550-9, 2015 Dec.

Article in En | MEDLINE | ID: mdl-26289591

Subject(s)

Antibiotics, Antineoplastic/therapeutic use; Antineoplastic Agents/therapeutic use; Everolimus/therapeutic use; Sirolimus/therapeutic use; TOR Serine-Threonine Kinases/antagonists & inhibitors; Tuberous Sclerosis/drug therapy; Animals; Brain Neoplasms/drug therapy; Clinical Trials as Topic; Female; Glioma, Subependymal/drug therapy; Humans; Male; Signal Transduction; TOR Serine-Threonine Kinases/metabolism; Treatment Outcome; Tuberous Sclerosis/genetics; Tuberous Sclerosis/metabolism; Tuberous Sclerosis Complex 1 Protein; Tuberous Sclerosis Complex 2 Protein; Tumor Suppressor Proteins/genetics

Key words

everolimus; mammalian target of rapamycin; sirolimus; tuberous sclerosis complex

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Tuberous Sclerosis / Sirolimus / TOR Serine-Threonine Kinases / Everolimus / Antibiotics, Antineoplastic / Antineoplastic Agents Type of study: Clinical_trials Limits: Animals / Female / Humans / Male Language: En Journal: Neuro Oncol Journal subject: NEOPLASIAS / NEUROLOGIA Year: 2015 Type: Article

Fulltext

XML

PubMed Links

Search on Google